Article

Study: coffee protects against blepharospasm

People who drink coffee are less likely to develop primary late-onset blepharospasm, according to results of a multicenter case control study conducted in Italy and published online ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

London-People who drink coffee are less likely to develop primary late-onset blepharospasm, according to results of a multicenter case control study conducted in Italy and published online ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

One to two cups per day were needed for the protective effect to be seen, and the effect was proportional to the amount of coffee consumed. Also, the age of onset of the eye spasm was found to be later in patients who drank more coffee: 1.7 years for each additional cup per day.

Previous studies have suggested that smoking protects against development of blepharospasm, but this study did not show a significant protective effect.

"The most obvious candidate for the protective effect is caffeine, but the low frequency of decaffeinated coffee intake in Italy prevented us from examining the effects of caffeine on blepharospasm," the authors wrote.

Caffeine may block adenosine receptors, they proposed.

"Considering that the caffeine content of a cup of Italian coffee (60 to 120 mg) is similar to the average content of a cup of American coffee (95 to 125 mg), the protective effect on the development of bleph-arospasm might be exerted at caffeine doses greater than 120 to 240 mg, comparable with the caffeine doses suggested to be protective in Parkinson's disease," according to the authors.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.